BioCentury
ARTICLE | Company News

Panel rebuffs Micardis for CV events in high risk patients

July 30, 2009 12:02 AM UTC

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 7-0 against approval of Micardis telmisartan from Boehringer Ingelheim GmbH (Ingelheim, Germany) to prevent cardiovascular events in patients at high risk of such events. The panel did vote 5-2 in favor of approval for patients who cannot tolerate ramipril. ...